CN101375161A - 靶定金黄色葡萄球菌ORF0657n的抗原结合蛋白 - Google Patents

靶定金黄色葡萄球菌ORF0657n的抗原结合蛋白 Download PDF

Info

Publication number
CN101375161A
CN101375161A CNA2007800036232A CN200780003623A CN101375161A CN 101375161 A CN101375161 A CN 101375161A CN A2007800036232 A CNA2007800036232 A CN A2007800036232A CN 200780003623 A CN200780003623 A CN 200780003623A CN 101375161 A CN101375161 A CN 101375161A
Authority
CN
China
Prior art keywords
seq
region
mab
amino acids
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800036232A
Other languages
English (en)
Chinese (zh)
Inventor
M·J·布朗
A·S·安德森
L·D·科普
K·U·延森
T·麦尼利
B·哈维
E·杜尔
R·埃恩斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of CN101375161A publication Critical patent/CN101375161A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CNA2007800036232A 2006-01-27 2007-01-23 靶定金黄色葡萄球菌ORF0657n的抗原结合蛋白 Pending CN101375161A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76302306P 2006-01-27 2006-01-27
US60/763,023 2006-01-27

Publications (1)

Publication Number Publication Date
CN101375161A true CN101375161A (zh) 2009-02-25

Family

ID=38327867

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800036232A Pending CN101375161A (zh) 2006-01-27 2007-01-23 靶定金黄色葡萄球菌ORF0657n的抗原结合蛋白

Country Status (7)

Country Link
US (1) US20110091480A1 (https=)
EP (1) EP1982185A4 (https=)
JP (1) JP2009524428A (https=)
CN (1) CN101375161A (https=)
AU (1) AU2007210170A1 (https=)
CA (1) CA2637152A1 (https=)
WO (1) WO2007089470A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0811193A2 (pt) * 2007-05-31 2014-11-11 Merck & Co Inc Proteína de ligação a antígeno isolada, ácido nucleico, célula recombinante, métodos para produzir uma proteína e para proteger ou tratar contra uma infecção por s. aureus em paciente, composição farmacêutica, uso da proteína de ligação a antígeno, e, polipeptídeo.
EP2185190B1 (en) 2007-08-31 2015-06-24 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
WO2010014304A1 (en) 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
ES2784957T3 (es) 2009-04-03 2020-10-02 Univ Chicago Composiciones y métodos relacionados con variantes de la proteína A (SPA)
JP6002128B2 (ja) 2010-07-02 2016-10-05 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ プロテインＡ（ＳｐＡ）変種に関連する組成物および方法
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
MX2021013833A (es) 2019-05-14 2022-03-17 Univ Chicago Metodos y composiciones que comprenden variantes de la proteina a de estafilococos (spa).
WO2021051136A1 (en) 2019-09-13 2021-03-18 The University Of Chicago Methods and compositions for treating staphylococcal infections
WO2022042673A1 (zh) * 2020-08-28 2022-03-03 江苏恒瑞医药股份有限公司 用于降低异源多肽末端异质性的信号肽

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6916605B1 (en) * 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
PT1377314E (pt) * 2001-01-26 2012-01-02 Inhibitex Inc Anticorpos monoclonais para a proteína clfa e método de utilização no tratamento ou prevenção de infecções
US20070275460A1 (en) * 2003-03-03 2007-11-29 Xencor.Inc. Fc Variants With Optimized Fc Receptor Binding Properties
ATE457737T1 (de) * 2003-07-24 2010-03-15 Merck & Co Inc Polypeptide zur induktion einer schützenden immunantwort gegen staphylococcus aureus
CN1980692A (zh) * 2003-07-24 2007-06-13 麦克公司 用于诱导针对金黄色葡萄球菌的保护性免疫反应的多肽
AU2006206577B2 (en) * 2005-01-21 2012-03-08 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against Staphylococcus aureus
EP2117574A4 (en) * 2007-01-24 2010-06-16 Merck Sharp & Dohme POLYPEPTIDES FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS EPIDERMIDIS
EP2126070A4 (en) * 2007-03-19 2010-03-31 Merck Sharp & Dohme POLYPEPTIDES FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS EPIDERMIDIS
BRPI0811193A2 (pt) * 2007-05-31 2014-11-11 Merck & Co Inc Proteína de ligação a antígeno isolada, ácido nucleico, célula recombinante, métodos para produzir uma proteína e para proteger ou tratar contra uma infecção por s. aureus em paciente, composição farmacêutica, uso da proteína de ligação a antígeno, e, polipeptídeo.

Also Published As

Publication number Publication date
WO2007089470A3 (en) 2008-01-24
EP1982185A2 (en) 2008-10-22
US20110091480A1 (en) 2011-04-21
WO2007089470A9 (en) 2007-11-01
WO2007089470A2 (en) 2007-08-09
CA2637152A1 (en) 2007-08-09
EP1982185A4 (en) 2010-04-28
JP2009524428A (ja) 2009-07-02
AU2007210170A1 (en) 2007-08-09

Similar Documents

Publication Publication Date Title
CN101375161A (zh) 靶定金黄色葡萄球菌ORF0657n的抗原结合蛋白
CN111690059B (zh) 一种抗SARS-CoV-2的单克隆抗体1D7
CN101679516B (zh) 靶向金黄色葡萄球菌ORF0657n的抗原结合蛋白
ES2308974T3 (es) Anticuerpos de il-18 recombinantes y su uso.
KR101363120B1 (ko) 항-인터페론 알파 모노클로날 항체 및 사용 방법
JP2021166538A (ja) ブラジキニンｂ１受容体リガンドに対する抗体
CA2230116A1 (en) Neutralizing monoclonal antibodies to respiratory syncytial virus
CN113015745B (zh) 针对金黄色葡萄球菌白细胞毒素的抗体
CN109843917B (zh) 抗o1抗体及其用途
CN113056480B (zh) 人源化抗N截短淀粉样β单克隆抗体
CN112094349A (zh) 靶向于白介素36r的抗体及其制备方法和应用
JP6371758B2 (ja) 抗ブドウ球菌抗体、その製造方法並びにその使用
CN108135999A (zh) 针对狂犬病的人抗体及其用途
CN112996815A (zh) 人pd-l1抗体
CN113416249B (zh) 针对破伤风毒素的组合物
WO2019128119A1 (zh) 一种针对破伤风毒素的全人源单克隆中和抗体及其应用
CN112375146B (zh) 检测Anti-CD19 CAR表达水平的抗独特性抗体及其应用
WO2021238854A1 (zh) 抗SARS-CoV-2刺突蛋白的单克隆抗体及其制备方法和用途
CN113817052A (zh) 抗SARS-CoV-2核衣壳蛋白单克隆抗体及其制备方法和用途
TWI814094B (zh) 貓抗體變異體
JP2007527703A (ja) 肺炎球菌表面付着因子Ａタンパク質（ＰｓａＡ）に関する結合メンバー
KR20170137111A (ko) 에스. 아우레우스의 면역글로불린 결합 단백질에 대해 지시된 항체
CN120590524B (zh) 具有广谱性中和牛病毒性腹泻病毒的单克隆抗体及其应用
HK40045762A (en) Human pd-l1 antibodies
MX2008005405A (es) Anticuerpos quimericos equinos: humanos.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20090225